Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors

Komal L. Jhaveri, MD, FACP
Published: Wednesday, Aug 29, 2018



Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Jhaveri says that taselisib is a potent, selective, oral inhibitor of class I PI3Kα, γ, and δ isoforms. In a phase I basket study (NCT01296555), the PI3K inhibitor taselisib was given to patients with PIK3CA-mutated solid tumors who had progressed after, or did not response to, at least 1 prior treatment.

There are 11 cohorts of patients with various solid tumors in the basket trial including endometrial, bladder, head and neck squamous cell carcinoma, cervical, gastric or gastroesophageal junction, small cell lung, triple-negative breast, colorectal, squamous, ovarian, and patients with tumors not otherwise specified. Patients on the study received either 4 mg or 6 mg of taselisib daily. The primary endpoint is safety and tolerability, with a secondary endpoint of antitumor activity.


Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Jhaveri says that taselisib is a potent, selective, oral inhibitor of class I PI3Kα, γ, and δ isoforms. In a phase I basket study (NCT01296555), the PI3K inhibitor taselisib was given to patients with PIK3CA-mutated solid tumors who had progressed after, or did not response to, at least 1 prior treatment.

There are 11 cohorts of patients with various solid tumors in the basket trial including endometrial, bladder, head and neck squamous cell carcinoma, cervical, gastric or gastroesophageal junction, small cell lung, triple-negative breast, colorectal, squamous, ovarian, and patients with tumors not otherwise specified. Patients on the study received either 4 mg or 6 mg of taselisib daily. The primary endpoint is safety and tolerability, with a secondary endpoint of antitumor activity.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x